SAN DIEGO, Jan. 23, 2020 /PRNewswire/ -- Johnson
Fistel, LLP announces that it has filed a class action lawsuit
on behalf of all those who purchased or otherwise acquired Geron
Corporation ("Geron") (NASDAQ: GERN) common stock during the period
between March 19, 2018 and
September 26, 2018, inclusive (the
"Class Period"). This action was filed in the United States District Court for the
Northern District of California,
case No. 3:20-cv-00547
The Private Securities Litigation Reform Act of 1995 permits any
investor who purchased or otherwise acquired Geron securities
during the Class Period to seek appointment as lead plaintiff.
A lead plaintiff acts on behalf of all other class members in
directing the litigation. The lead plaintiff can select a law
firm of its choice. An investor's ability to share in any
potential future recovery is not dependent upon serving as lead
plaintiff. If you wish to serve as lead plaintiff, you must
move the Court no later 60 days from today. If you
wish to discuss this action or have any questions concerning this
notice or your rights or interests, please contact Jim Baker (jimb@johnsonfistel.com)
at 619-814-4471. If emailing, please include a phone
number.
Additionally, you can [Click here to join this action].
There is no cost or obligation to you.
The complaint alleges that defendants: (1) misled investors
about the results of a clinical drug study of imetelstat called
IMbark; and (2) as a result, defendants' statements about Geron's
business, operations, and prospects were materially false and
misleading and lacked a reasonable basis at all relevant times.
When the true details entered the market, the lawsuit claims
that investors suffered damages.
Imetelstat was intended to treat certain cancers that occur in
bone marrow, and the IMbark study was designed to ascertain whether
imetelstat helped patients with a cancer called myelofibrosis.
Geron was developing imetelstat in partnership with Janssen
Biotech Inc. ("Janssen"), a division of Johnson & Johnson.
On September 27, 2018, Geron
issued a press release stating that patients in the IMbark study
had shown only a 10% spleen response rate and a 32% symptom
response rate. The Company also announced that Janssen had
terminated its partnership with Geron for the development of
imetelstat.
Plaintiff seeks to recover damages on behalf of all those who
purchased or otherwise acquired Geron securities during the Class
Period.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York, and Georgia.
The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits.
For more information about the firm and its attorneys, please
visit https://www.johnsonfistel.com. Attorney advertising.
Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
[Click here to join this action]
View original
content:http://www.prnewswire.com/news-releases/johnson-fistel-llp-announces-that-it-has-filed-a-class-action-against-geron-corporation-300992609.html
SOURCE Johnson Fistel, LLP